NASDAQ:JUNS Jupiter Neurosciences Q1 2025 Earnings Report $4.18 -0.71 (-14.52%) As of 08/28/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Jupiter Neurosciences EPS ResultsActual EPS-$3.75Consensus EPS -$2.25Beat/MissMissed by -$1.50One Year Ago EPSN/AJupiter Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AJupiter Neurosciences Announcement DetailsQuarterQ1 2025Date5/15/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsJupiter Neurosciences' next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Jupiter Neurosciences Earnings HeadlinesJupiter Neurosciences (JUNS) Projected to Release Quarterly Earnings on WednesdayAugust 26, 2026 | americanbankingnews.comJupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingAugust 22, 2026 | finanznachrichten.deIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.August 30 at 1:00 AM | Porter & Company (Ad)Jupiter Neurosciences stock surges Friday: What's driving the action?August 21, 2026 | msn.comJupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingAugust 21, 2026 | globenewswire.comJupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026August 5, 2026 | quiverquant.comQSee More Jupiter Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jupiter Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jupiter Neurosciences and other key companies, straight to your email. Email Address About Jupiter NeurosciencesJupiter Neurosciences (NASDAQ:JUNS), a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.View Jupiter Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekRubrik’s AI Security Bet Could Power the Next Leg HigherIREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings3 Financial Stocks Positioned for the Fed’s Next Move After Jackson HoleNutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
